share_log

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

CytoMed Therapeuticsは、同種異系γδT細胞技術の研究を推進するためのHOAおよびMOUに署名します。

Benzinga ·  2023/12/05 07:34

CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that it has entered into a Heads of Agreement (HOA) with CytoMed Therapeutics China Limited (CytoMed China), a company incorporated in Hong Kong and a Memorandum of Understanding (MOU) with BioNex Solutions Inc., 千尋生命科學.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする